ABVX Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Benzinga - Mentions: CAH ELAN GH MEDP ...

6 Healthcare Stocks With Strong Upward Momentum

7 days ago - By: The Motley Fool - Mentions: AMLX CGON COGT CNTA

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead

7 days ago - By: The Motley Fool - Mentions: LQDA CGON COGT AMLX ...

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch

2 months ago - By: Benzinga

Why Is Abivax Stock Trading Higher On Monday?

11 days ago - By: Zacks Investment Research

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know

11 days ago - By: Zacks Investment Research - Mentions: CPRX

Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?

21 days ago - By: Abivax

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

21 days ago - By: Abivax

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

2 months ago - By: Investor's Business Daily - Mentions: AAPL

Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease

2 months ago - By: Abivax

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

2 months ago - By: Abivax

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

2 months ago - By: Abivax

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

2 months ago - By: Abivax

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

2 months ago - By: Abivax

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

2 months ago - By: Abivax

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

2 months ago - By: Abivax

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

2 months ago - By: Abivax

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

2 months ago - By: Abivax

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

2 months ago - By: Abivax

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

3 months ago - By: Abivax

Abivax Presents First Half 2025 Financial Results

3 months ago - By: Abivax

Abivax Presents First Half 2025 Financial Results

4 months ago - By: Abivax

Abivax Announces Closing of $747.5 Million Public Offering

4 months ago - By: Abivax

Abivax Announces Closing of $747.5 Million Public Offering

4 months ago - By: Abivax

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

4 months ago - By: Abivax

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

4 months ago - By: Abivax

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

4 months ago - By: Abivax

Abivax announces trading resumption of its ordinary shares on Euronext Paris

4 months ago - By: Abivax

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

4 months ago - By: Abivax

ABIVAX SA-ADR (ABVX) Stock News

ABVX Latest News, Press Relases and Analysis